Investigators established a cellular model system using a CD19-positive B lineage acute lymphoblastic leukemia (B-ALL) cell line Nalm-6 to investigate the treatment options for CD19-negative relapsed B-ALL after CD19-CAR T cell therapy.
[Apoptosis]